NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation
Leukemia · 2025
DOI: 10.1038/s41375-024-02438-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia, 2025. Verfasst von Yuko Shimosato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tok…. Hauptthemen laut MEDLINE: Nucleophosmin, Exportin 1 Protein, Karyopherins, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nucleophosmin ( NPM1 ) is a nucleolar protein and one of the most frequently mutated genes in acute myeloid leukemia (AML). In addition to the commonly detected frameshift mutations in exon12 (NPM1c), previous studies have identified NPM1 gene rearrangements leading to the expression of NPM1-fusion proteins in pediatric AML. However, whether the NPM1-fusions are indeed oncogenic and how the NPM1-fusions cause AML have been largely unknown. In this study, we investigated the subcellular localization and leukemogenic potential of two rare NPM1-fusion proteins, NPM1::MLF1 and NPM1::CCDC28A. NPM1::MLF1 is present in both the nucleus and cytoplasm and occasionally induces AML in the mouse transplantation assay. NPM1::CCDC28A is more localized to the cytoplasm, immortalizes mouse bone marrow cells in vitro and efficiently induces AML in vivo. Mechanistically, both NPM1-fusions bind to the HOX gene cluster and, like NPM1c, cause aberrant upregulation of HOX genes in cooperation with XPO1. The XPO1 inhibitor selinexor suppressed HOX activation and colony formation driven by the NPM1-fusions. NPM1::CCDC28A cells were also sensitive to menin inhibition. Thus, our study provides experimental evidence that both NPM1::MLF1 and NPM1::CCDC28A are oncogenes with functions similar to NPM1c. Inhibition of XPO1 and menin may be a promising strategy for the NPM1-rearranged AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
- Department of Pediatrics, Yokohama City University Hospital, Yokohama, Japan.
- Department of Hematology/Oncology, Gunma Children's Medical Center, Shibukawa, Japan.
- Division of Molecular Pharmacology of Malignant Diseases, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
- Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan.
- Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. goyama@edu.k.u-tokyo.ac.jp.
Zitieren
APA
Shimosato, Y., Yamamoto, K., Jia, Y., Zhang, W., Shiba, N., Hayashi, Y., Ito, S., Kitamura, T., & Goyama, S. (2025). NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation. Leukemia. https://doi.org/10.1038/s41375-024-02438-w
Vancouver
Shimosato Y, Yamamoto K, Jia Y, Zhang W, Shiba N, Hayashi Y, et al. NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation. Leukemia. 2025. doi:10.1038/s41375-024-02438-w
BibTeX
@article{Shimosato2025,
author = {Shimosato, Yuko and Yamamoto, Keita and Jia, Yuhan and Zhang, Wenyu and Shiba, Norio and Hayashi, Yasuhide and Ito, Shuichi and Kitamura, Toshio and Goyama, Susumu},
title = {NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation},
journal = {Leukemia},
year = {2025},
doi = {10.1038/s41375-024-02438-w}
}
EUVIMED